cabergoline has been researched along with Disease Models, Animal in 34 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.94) | 18.2507 |
| 2000's | 11 (32.35) | 29.6817 |
| 2010's | 18 (52.94) | 24.3611 |
| 2020's | 4 (11.76) | 2.80 |
| Authors | Studies |
|---|---|
| Abrams, RPM; Bachani, M; Balasubramanian, A; Brimacombe, K; Dorjsuren, D; Eastman, RT; Hall, MD; Jadhav, A; Lee, MH; Li, W; Malik, N; Nath, A; Padmanabhan, R; Simeonov, A; Steiner, JP; Teramoto, T; Yasgar, A; Zakharov, AV | 1 |
| Kimura, T; Kinoshita, I; Kon, T; Miki, Y; Mori, F; Nakamura, T; Nishijima, H; Suzuki, C; Tomiyama, M; Wakabayashi, K | 1 |
| Karasu, AFG; Karslıoglu, T; Yildiz, P | 1 |
| Erbas, O; Hortu, I; Karadadas, E; Ozceltik, G; Tavmergen Goker, EN; Tavmergen, E; Yigitturk, G | 1 |
| Ali, F; Fatima, A; Khan, W; Khanam, S; Naqvi, AH; Naz, F; Siddique, YH; Singh, BR; Smita Jyoti, R | 1 |
| Cao, H; Chen, L; Li, X; Shen, X; Shi, R; Wang, D; Xia, Q; Xu, H; Xue, F; Yang, H; Yuan, W; Zhao, X; Zheng, J | 1 |
| Fatemi, F; Jouhari, S; Khazali, S; Lakpour, N; Mirzadegan, E; Mohammadi, Z; Mohammadzadeh, A; Mohazzab, A; Naderi, MM; Soltanghoraee, H; Zafardoust, S | 1 |
| Atilgan, R; Başpınar, M; Ilhan, N; Pala, Ş; Yavuzkır, Ş; Yılmaz, M | 1 |
| Bougeret, C; Corachán, A; Domínguez, F; Ferrero, H; Pellicer, A; Pouletty, P; Quiñonero, A | 1 |
| Deveer, R; Engin-Ustun, Y; Moraloglu, O; Timur, H; Ustun, Y; Yılmaz, N; Yılmaz, S | 1 |
| Chen, T; Feng, BS; Geng, XR; Liu, C; Liu, Z; Sun, M; Wu, R; Wu, W; Yang, G; Yang, PC; Zhang, HP | 1 |
| Aydogan, U; Cengiz, M; Ercan, CM; Ergun, A; Ide, T; Kayaalp, O; Keskin, U; Yumusak, N | 1 |
| Ahluwalia, A; Deng, X; Ostapchenko, L; Paunovic, B; Prysiazhniuk, A; Sandor, Z; Szabo, S; Tarnawski, A; Tolstanova, G | 1 |
| Akan, Z; Cengiz, H; Eskicioğlu, F; Sahin, N; Sivrikoz, ON; Turan, GA; Vatansever, S; Yeşil, H; Yilmaz, O; Zafer, A | 1 |
| Hiratochi, M; Ijiro, T; Kaidoh, K; Oana, F; Suzuki, T; Tsuchioka, A; Yamauchi, Y | 1 |
| Cengiz, H; Eskicioğlu, F; Genc, M; Gur, EB; Kasap, E; Sivrikoz, ON; Turan, GA; Yılmaz, O | 1 |
| Ferrario, JE; Gershanik, OS; Larramendy, C; Murer, MG; Saborido, MD; Taravini, IR | 1 |
| Camras, C; Crosson, C; Drace, C; Husain, S; Katoli, P; Kelly, CR; McLaughlin, MA; Sharif, NA; Toris, C; Zhan, GL | 1 |
| Carda, C; García-Velasco, JA; Noguera, I; Novella-Maestre, E; Pellicer, A; Ruiz-Saurí, A; Simón, C | 1 |
| Bélanger, N; Di Paolo, T; Hadj Tahar, A; Morissette, M; Samadi, P | 1 |
| Arioz, DT; Dilek, H; Koken, T; Saylan, A; Saylan, F; Yilmazer, M | 1 |
| Chiba, S; Kunugi, H; Ninomiya, M; Numakawa, T; Yoon, HS | 1 |
| Delgado-Rosas, F; Ferrero, H; Garcia-Velasco, J; Gaytan, F; Gómez, R; Pellicer, A; Simón, C | 1 |
| Carda, C; Herraiz, S; Novella-Maestre, E; Pellicer, A; Ruiz-Sauri, A; Vila-Vives, JM | 1 |
| Ahtiainen, P; Calandra, RS; Di Giorgio, NP; Gonzalez, B; Huhtaniemi, IT; Poutanen, M; Ratner, LD; Rulli, SB | 1 |
| Appiah-Kubi, LS; Chaudhuri, KR; Marco, AD | 1 |
| Bédard, PJ; Bélanger, N; Grégoire, L; Hadj Tahar, A | 1 |
| Battaglia, A; Canonico, PL; Francioli, E; Lombardi, G; Miglio, G; Varsaldi, F | 1 |
| Ogawa, N; Tanaka, K | 1 |
| Alonso-Muriel, I; Gomez, R; Gonzalez-Izquierdo, M; Novella-Maestre, E; Pellicer, A; Remohi, J; Sanchez-Criado, J; Simon, C; Zimmermann, RC | 1 |
| Inada, Y; Kojima, M; Komatsu, H; Miyata, H; Moro, M; Torii, R | 1 |
| Bédard, PJ; Di Paolo, T; Falardeau, P; Goulet, M; Grondin, R; Maltais, S; Morissette, M | 1 |
| Bédard, PJ; Blanchet, PJ; Calon, F; Di Paolo, T; Goulet, M; Grondin, R; Lévesque, D; Morissette, M | 1 |
| Abe, K; Kashihara, K; Manabe, Y; Murakami, T | 1 |
1 review(s) available for cabergoline and Disease Models, Animal
| Article | Year |
|---|---|
Use of the dopamine agonist cabergoline in the treatment of movement disorders.
Topics: Antiparkinson Agents; Cabergoline; Disease Models, Animal; Dopamine Agonists; Ergolines; Humans; Movement Disorders; Neuroprotective Agents; Parkinson Disease | 2002 |
1 trial(s) available for cabergoline and Disease Models, Animal
| Article | Year |
|---|---|
The Effects of Micronized Progesterone and Cabergoline On a Rat Autotransplantation Endometriosis Model: A Placebo Controlled Randomized Trial.
Topics: Animals; Cabergoline; Disease Models, Animal; Endometriosis; Female; Humans; Progesterone; Rats; Rats, Sprague-Dawley; Rats, Wistar; Transplantation, Autologous | 2021 |
32 other study(ies) available for cabergoline and Disease Models, Animal
| Article | Year |
|---|---|
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Immunocompetence; Inhibitory Concentration 50; Methacycline; Mice, Inbred C57BL; Protease Inhibitors; Quantitative Structure-Activity Relationship; Small Molecule Libraries; Vero Cells; Zika Virus; Zika Virus Infection | 2020 |
Cabergoline, a long-acting dopamine agonist, attenuates L-dopa-induced dyskinesia without L-dopa sparing in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Cabergoline; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; RNA, Messenger | 2022 |
Oxytocin and cabergoline alleviate ovarian hyperstimulation syndrome (OHSS) by suppressing vascular endothelial growth factor (VEGF) in an experimental model.
Topics: Animals; Cabergoline; Disease Models, Animal; Female; Ovarian Hyperstimulation Syndrome; Oxytocics; Oxytocin; Rats; Rats, Sprague-Dawley; Rats, Wistar; Vascular Endothelial Growth Factor A | 2021 |
Effect of cabergoline alginate nanocomposite on the transgenic Drosophila melanogaster model of Parkinson's disease.
Topics: Alginates; alpha-Synuclein; Animals; Animals, Genetically Modified; Behavior, Animal; Cabergoline; Disease Models, Animal; Dopamine; Dopamine Agonists; Dose-Response Relationship, Drug; Drosophila melanogaster; Longevity; Nanocomposites; Oxidative Stress; Parkinson Disease | 2018 |
Local production of prolactin in lesions may play a pathogenic role in psoriatic patients and imiquimod-induced psoriasis-like mouse model.
Topics: Adult; Aged; Animals; Cabergoline; Cytokines; Dermis; Disease Models, Animal; Dopamine Agonists; Epidermis; Female; Humans; Imiquimod; Male; Methylcellulose; Mice; Middle Aged; Prolactin; Psoriasis; Receptors, Prolactin; Risk Adjustment; RNA, Messenger; Solvents; TRPV Cation Channels | 2018 |
Effects of silymarin, cabergoline and letrozole on rat model of endometriosis.
Topics: Animals; Antioxidants; Aromatase Inhibitors; Cabergoline; Disease Models, Animal; Dopamine Agonists; Endometriosis; Female; Letrozole; Random Allocation; Rats; Rats, Sprague-Dawley; Silymarin; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A | 2018 |
What is the impact of short- and long-term supplementation of either cabergoline or clarithromycin on resolving rat ovarian hyperstimulation syndrome (OHSS) model?
Topics: Animals; Anti-Bacterial Agents; Cabergoline; Chorionic Gonadotropin; Clarithromycin; Disease Models, Animal; Dopamine Agonists; Estradiol; Female; Gonadotropins, Equine; Interleukin-10; Interleukin-1beta; Ovarian Hyperstimulation Syndrome; Rats; Rats, Wistar; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A | 2019 |
Inhibition of KIF20A by BKS0349 reduces endometriotic lesions in a xenograft mouse model.
Topics: Animals; Apoptosis; Cabergoline; Cell Proliferation; Disease Models, Animal; Endometriosis; Endometrium; Female; Heterografts; Humans; Kinesins; Mice; Mice, Nude; Optical Imaging; Peritoneal Diseases | 2019 |
Comparison of bevacizumab and cabergoline in the treatment of ovarian hyperstimulation syndrome in a rat model.
Topics: Animals; Antibodies, Monoclonal, Humanized; Bevacizumab; Cabergoline; Cell Count; Disease Models, Animal; Drug Evaluation, Preclinical; Ergolines; Female; Organ Size; Ovarian Hyperstimulation Syndrome; Ovary; Ovum; Rats; Rats, Wistar | 2013 |
Prolactin mediates psychological stress-induced dysfunction of regulatory T cells to facilitate intestinal inflammation.
Topics: Animals; Cabergoline; Colitis; Dextran Sulfate; Disease Models, Animal; Dopamine Agonists; Ergolines; Forkhead Transcription Factors; Immunity, Mucosal; Inflammation; Interleukins; Mice; Mice, Inbred BALB C; Prolactin; Stress, Psychological; T-Lymphocytes, Regulatory; Trinitrobenzenesulfonic Acid; Tumor Necrosis Factor-alpha | 2014 |
Comparison of efficacy of bromocriptine and cabergoline to GnRH agonist in a rat endometriosis model.
Topics: Adult; Animals; Antineoplastic Agents; Bromocriptine; Cabergoline; Disease Models, Animal; Dopamine Agonists; Endometriosis; Endometrium; Ergolines; Female; Gonadotropin-Releasing Hormone; Humans; Laparotomy; Leuprolide; Prospective Studies; Random Allocation; Rats; Rats, Wistar; Triptorelin Pamoate | 2015 |
Role of Dopamine and D2 Dopamine Receptor in the Pathogenesis of Inflammatory Bowel Disease.
Topics: Animals; Biopsy, Needle; Blotting, Western; Cabergoline; Capillary Permeability; Colitis, Ulcerative; Disease Models, Animal; Dopamine; Ergolines; Female; Humans; Immunohistochemistry; Inflammation Mediators; Inflammatory Bowel Diseases; Interleukin-10; Iodoacetamide; Mice; Mice, Inbred C57BL; Mice, Knockout; Quinpirole; Random Allocation; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Statistics, Nonparametric | 2015 |
Montelukast is effective in preventing of ovarian hyperstimulation syndrome; an experimental study.
Topics: Acetates; Animals; Cabergoline; Chorionic Gonadotropin; Cyclopropanes; Disease Models, Animal; Dose-Response Relationship, Drug; Ergolines; Female; Ovarian Hyperstimulation Syndrome; Ovary; Quinolines; Random Allocation; Rats; Rats, Wistar; Sulfides | 2015 |
Duration of drug action of dopamine D2 agonists in mice with 6-hydroxydopamine-induced lesions.
Topics: Animals; Antiparkinson Agents; Apomorphine; Azepines; Benzothiazoles; Cabergoline; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; Ergolines; Indoles; Injections, Intraventricular; Male; Mice; Motor Activity; Oxidopamine; Parkinsonian Disorders; Pramipexole; Quinolines; Receptors, Dopamine D2; Tetrahydronaphthalenes; Thiophenes | 2015 |
Comparison between resveratrol and cabergoline in preventing ovarian hyperstimulation syndrome in a rat model.
Topics: Animals; Antioxidants; Cabergoline; Disease Models, Animal; Dopamine Agonists; Ergolines; Female; Ovarian Hyperstimulation Syndrome; Ovary; Random Allocation; Rats; Rats, Wistar; Resveratrol; Stilbenes | 2016 |
Cabergoline and pramipexole fail to modify already established dyskinesias in an animal model of parkinsonism.
Topics: Amphetamine; Animals; Antiparkinson Agents; Behavior, Animal; Benzothiazoles; Cabergoline; Disease Models, Animal; Dopamine Antagonists; Drug Interactions; Dyskinesia, Drug-Induced; Ergolines; Female; Levodopa; Mesencephalon; Oxidopamine; Parkinsonian Disorders; Pramipexole; Rats; Rats, Wistar; Stereotyped Behavior; Tyrosine 3-Monooxygenase | 2008 |
Cabergoline: Pharmacology, ocular hypotensive studies in multiple species, and aqueous humor dynamic modulation in the Cynomolgus monkey eyes.
Topics: Animals; Antihypertensive Agents; Aqueous Humor; Biological Availability; Cabergoline; Calcium; Cats; Cells, Cultured; CHO Cells; Cricetinae; Cricetulus; Disease Models, Animal; Drug Evaluation, Preclinical; Ergolines; Humans; Intraocular Pressure; Macaca fascicularis; Ocular Hypertension; Rabbits; Rats; Species Specificity | 2009 |
Dopamine agonist administration causes a reduction in endometrial implants through modulation of angiogenesis in experimentally induced endometriosis.
Topics: Animals; Cabergoline; Cell Proliferation; Disease Models, Animal; Dopamine Agonists; Endometriosis; Ergolines; Female; Gene Expression Regulation; Humans; Mice; Neovascularization, Pathologic; Phosphorylation; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2009 |
Striatal Akt/GSK3 signaling pathway in the development of L-Dopa-induced dyskinesias in MPTP monkeys.
Topics: Animals; Antiparkinson Agents; Benzoxazoles; Cabergoline; Corpus Striatum; Disease Models, Animal; Drug Interactions; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Ergolines; Female; Glycogen Synthase Kinase 3; Levodopa; Macaca fascicularis; Oncogene Protein v-akt; Parkinsonian Disorders; Phosphorylation; Piperidines; Serine; Signal Transduction; Statistics as Topic | 2010 |
Prevention of ovarian hyperstimulation syndrome in a rat model: efficacy comparison between cabergoline and meloxicam.
Topics: Analysis of Variance; Animals; Biopsy, Needle; Body Weight; Cabergoline; Chorionic Gonadotropin; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Ergolines; Female; Immunohistochemistry; Injections, Intramuscular; Meloxicam; Organ Size; Ovarian Hyperstimulation Syndrome; Ovary; Ovulation Induction; Pregnancy; Pregnancy, Animal; Probability; Random Allocation; Rats; Rats, Wistar; Thiazines; Thiazoles; Vascular Endothelial Growth Factor A | 2010 |
Cabergoline, a dopamine receptor agonist, has an antidepressant-like property and enhances brain-derived neurotrophic factor signaling.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain-Derived Neurotrophic Factor; Cabergoline; Depression; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Ergolines; Fluvoxamine; Hippocampus; Male; Mitogen-Activated Protein Kinase 3; Rats; Rats, Inbred WKY; Rats, Wistar; Signal Transduction; Up-Regulation | 2010 |
The effects of ergot and non-ergot-derived dopamine agonists in an experimental mouse model of endometriosis.
Topics: Animals; Blood Vessels; Cabergoline; Cell Count; Cell Proliferation; Claviceps; Disease Models, Animal; Dopamine Agonists; Endometriosis; Endometrium; Ergolines; Female; Humans; Mice; Neovascularization, Pathologic; Receptors, Dopamine D2; Uterine Diseases; Vascular Endothelial Growth Factor Receptor-2 | 2011 |
Effect of antiangiogenic treatment on peritoneal endometriosis-associated nerve fibers.
Topics: Actins; Angiogenesis Inhibitors; Animals; Biomarkers; Cabergoline; Disease Models, Animal; Endometriosis; Endometrium; Ergolines; Female; Fluorescent Antibody Technique; Humans; Immunohistochemistry; Macrophages; Mast Cells; Mice; Mice, Nude; Microvessels; Neovascularization, Pathologic; Nerve Fibers; Ovariectomy; Peritoneal Diseases; Time Factors; von Willebrand Factor | 2012 |
Short-term pharmacological suppression of the hyperprolactinemia of infertile hCG-overproducing female mice persistently restores their fertility.
Topics: Animals; Bromocriptine; Cabergoline; Chorionic Gonadotropin; Disease Models, Animal; Ergolines; Female; Fertility; Gene Expression Regulation; Humans; Hyperprolactinemia; Infertility; Mice; Mice, Transgenic; Ovulation; Phenotype; Time Factors | 2012 |
Chronic treatment with small doses of cabergoline prevents dopa-induced dyskinesias in parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Cabergoline; Disease Models, Animal; Dopamine Agonists; Drug Administration Schedule; Dyskinesia, Drug-Induced; Ergolines; Female; Locomotion; Macaca fascicularis; Parkinson Disease; Posture | 2003 |
Cabergoline protects SH-SY5Y neuronal cells in an in vitro model of ischemia.
Topics: Animals; Antioxidants; Cabergoline; Cell Death; Cell Hypoxia; Cell Line, Transformed; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Ergolines; Free Radical Scavengers; Free Radicals; Gene Expression; Genes, bcl-2; Glucose; Haloperidol; Humans; Ischemia; Neurons; Thiobarbituric Acid Reactive Substances; Time Factors; Tretinoin; Vitamin E | 2004 |
Dopamine agonist cabergoline inhibits levodopa-induced caspase activation in 6-OHDA-lesioned mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Cabergoline; Carbidopa; Caspases; Disease Models, Animal; Dopamine; Dopamine Agents; Dopamine Agonists; Drug Combinations; Drug Interactions; Enzyme Activation; Ergolines; Glutathione; Homovanillic Acid; Levodopa; Male; Mice; Mice, Inbred ICR; Neurotoxicity Syndromes; Oxidopamine; Thiobarbituric Acid Reactive Substances | 2005 |
Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model.
Topics: Animals; Cabergoline; Capillary Permeability; Corpus Luteum; Disease Models, Animal; Dopamine Agonists; Ergolines; Female; Neovascularization, Physiologic; Ovarian Hyperstimulation Syndrome; Phosphorylation; Rats; Rats, Wistar; Receptors, Dopamine D2; RNA, Messenger; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2006 |
New hyperprolactinemia and anovulation model in common marmoset (Callithrix jacchus) and effect of cabergoline.
Topics: Animals; Anovulation; Bromocriptine; Cabergoline; Callithrix; Disease Models, Animal; Dopamine Agonists; Dopamine Antagonists; Ergolines; Estradiol; Female; Hyperprolactinemia; Menstrual Cycle; Progesterone; Prolactin; Sulpiride; Time Factors | 1999 |
Regulation by chronic treatment with cabergoline of dopamine D1 and D2 receptor levels and their expression in the striatum of Parkinsonian-monkeys.
Topics: Animals; Antiparkinson Agents; Binding Sites; Cabergoline; Disease Models, Animal; Ergolines; Female; In Situ Hybridization; Macaca fascicularis; Parkinson Disease; Receptors, Dopamine D1; Receptors, Dopamine D2 | 2000 |
Regulation of dopamine receptors and motor behavior following pulsatile and continuous dopaminergic replacement strategies in the MPTP primate model.
Topics: Aminoquinolines; Animals; Behavior, Animal; Benzazepines; Cabergoline; Disease Models, Animal; Dopamine Agonists; Ergolines; Female; Gene Expression; Imidazoles; Infusion Pumps, Implantable; Macaca fascicularis; Motor Activity; Parkinsonian Disorders; Pulse Therapy, Drug; Receptors, Dopamine; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Dopamine D3; RNA, Messenger | 2001 |
Effects of short- and long-acting dopamine agonists on sensitized dopaminergic neurotransmission in rats with unilateral 6-OHDA lesions.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Cabergoline; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; Drug Antagonism; Ergolines; Levodopa; Male; Oxidopamine; Rats; Rats, Sprague-Dawley; Stereotyped Behavior; Synaptic Transmission | 2002 |